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United Kingdom; and §AstraZeneca R & D, Mo¨lndal, SwedenABSTRACT A wide range of ion channels have been considered as potential targets for pharmacological treatment of atrial
fibrillation. The Kv1.5 channel, carrying the IKur current, has received special attention because it contributes to repolarization
in the atria but is absent or weakly expressed in ventricular tissue. The dog serves as an important animal model for electrophys-
iological studies of the heart and mathematical models of the canine atrial action potential (CAAP) have been developed to study
the interplay between ionic currents. To enable more-realistic studies on the effects of Kv1.5 blockers on the CAAP in silico, two
continuous-time Markov models of the guarded receptor type were formulated for Kv1.5 and subsequently inserted into the
Ramirez-Nattel-Courtemanche model of the CAAP. The main findings were: 1), time- and state-dependent Markov models of
open-channel Kv1.5 block gave significantly different results compared to a time- and state-independent model with a down-
scaled conductance; 2), the outcome of Kv1.5 block on the macroscopic system variable APD90 was dependent on the precise
mechanism of block; and 3), open-channel block produced a reverse use-dependent prolongation of APD90. This study suggests
that more-complex ion-channel models are a prerequisite for quantitative modeling of drug effects.INTRODUCTIONThe ultrarapidly activating delayed rectifier Kþ current,
commonly denoted IKur, conducted by the Kv1.5 channel,
has emerged as a target for pharmacological treatment of
atrial fibrillation (AF; see Tamargo et al. (1) and references
within). IKur contributes to both early and late repolarization
of the action potential (AP) of the human atrial myocyte and
because a similar current largely seems to be lacking in
ventricular tissue, a blocker of the Kv1.5 channel would
have potential to selectively increase the duration of the
atrial AP (APD) and, hence, the refractory period (AERP).
IKur blockers have been shown to affect human atrial AP
repolarization in vitro, and selectively increase atrial refrac-
toriness and terminate atrial arrhythmias in several animal
species in vivo (2–8). Human in vitro data as well as
computer modeling of human atrial cells using Hodgkin-
Huxley representations of IKur have also shown that the
effect of a block of IKur on AP repolarization depend on
the relative densities of all involved ion channels and may
be more effective in diseased tissue (3,9). In both animal
disease models and humans, ion channel densities changes
during progression of AF (see Tamargo et al. (1) and refer-
ences within), thus changing the relative contribution of
each involved ion channel in the repolarization process.
This remodeling process also facilitates the progression of
the disease. In a complex biological system with interwoven
dependencies like this, good knowledge of the behavior of
individual components in isolation does not automatically
provide good knowledge of the behavior of the system as
a whole. Mathematical modeling may be especially helpful
in elucidating important system properties by combiningSubmitted March 29, 2010, and accepted for publication August 27, 2010.
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components. For example, complete models of the human
atrial myocyte AP have been developed (10,11) and exten-
sions of these models have been used to evaluate the effects
of IKur block (3,9).
Animal models are used extensively throughout the drug
development process from early discovery to late develop-
ment, to improve understanding of biological mechanisms,
and to allow for predictions of human responses to drug
exposure. For this reason, mathematical models of animal
models are of interest. Different animal models are used
in different disease areas and for cardiovascular diseases,
experimental dog models have been widely used to study,
for example, atrial arrhythmia mechanisms in vivo. The
Ramirez-Nattel-Courtemanche (RNC) model (12) is a math-
ematical model of the canine atrial AP. It is based on the
Hodgkin-Huxley formalism, contains all major ionic
currents, and has been validated using experimental mea-
surements in canine atrial myocytes. In this model, the
IKur current carried by Kv1.5 is known as IKurd.
However, most Kv1.5 blockers are selectively blocking
only the activated or open state of Kv1.5 channels (2,13–18)
and important features of the drug-ion channel interaction
such as use- and voltage-dependence are not easily imple-
mented in the Hodgkin-Huxley formalism. Rather than
using the Hodgkin-Huxley formulation, state-dependent
blocking mechanisms are usually modeled with Markov
models. Therefore, a continuous-time Markov model of the
guarded receptor type was set up for the canine Kv1.5 to
enable studies on the effects of Kv1.5 open-channel blockers
on the canine atrial AP in silico. Conceptually similar
Markov models have previously been successfully used to
describe the kinetics of block of human Kv1.5 by quinidine
(13), quinine, clofilium, and tetrapentylammonium (14),doi: 10.1016/j.bpj.2010.08.062
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Markov model was subsequently inserted into the RNC
model, replacing the original Hodgkin-Huxley expression.
A subset of the parameters in our model reflects properties
of a drug and drug-channel interactions such as the net charge
of a drug, and the rates of binding to, and dissociation from,
the receptor site on the channel. By performing simulations
with the modified version of the RNC model, we have been
able to examine the influence of these drug-defining param-
eters on theAP. Themodel has also been used tomake predic-
tions about the morphological changes of the AP for two
particular IKur blockers, whose kinetic parameters have
been determined experimentally elsewhere (2). In connec-
tion to this, our model of open-channel Kv1.5 block was
extended to also account for drugs that, like the above-exem-
plified compounds, exhibit a voltage-dependent dissociation
rate distinguished from the type of voltage dependence
caused by drugs carrying a net charge. To our knowledge,
this phenomenon has not been captured in any previous
Kv1.5 Markov model.METHODS
The RNC model
Canine atrial myocytes displays regional variations in ionic current density
(12). In this study, values for cells from the pectinate muscle (PM) were
used, and as described in Ramirez et al. (12), the maximum conductance
of L-type Ca 2þ channels, transient outward Kþ current, and Naþ channels
were set to 40%, 40%, and 50%, respectively, of their nominal values to
account for the major changes in ion channel density that occurs during
progression of AF in the dog (19). An often-encountered issue with models
of electrophysiological systems is small drifts in ion concentrations. In our
implementation, the ion concentrations of Naþ, Kþ, and Cl– were, for
simplicity, fixed to their initial values as listed in Ramirez et al. (12).
This did not alter the behavior of the model in any noticeable way except
for the loss of dynamics for these ion concentrations.Our Kv1.5 models
Transition rates between states in the models are assumed to have an expo-
nential voltage dependence and are characterized by two parameters—the
zero voltage rate and the equivalent charge movement up to the transition
state. The parameters in our five-state Kv1.5 model were optimized to
reproduce the behavior of the original RNC model. This optimization
was performed using a multidimensional downhill simplex method (20)
implemented in the Systems Biology Toolbox for MATLAB (The Math-
Works, Natick, MA) (21,22). The model reduction used in connection
with our 10-state model is based on an analytical equilibrium solution (23).Simulations
Simulations were performed with the Systems Biology Toolbox for
MATLAB (21,22), which uses the CVODE integrator (24). For all stimula-
tion frequencies, a stimulation current of 2900 pA was applied during
2 ms. Simulation data used for analysis was always collected from the
last of a series of 40 APs. This gave a maximum difference in membrane
potential between the last two APs equal to 0.01 and 0.05 mV for AF re-
modeled cells stimulated at frequencies of 1 and 4 Hz, respectively. Visual
inspections of APs and of the difference between consecutive APs was also
performed to ensure that the AP waveforms really were converging towardstable limit cycles. As a measure of APD, we used APD90, which was
defined as the time it takes, after a stimulation, to reach a voltage level of
72 mV. This corresponds to a 90% repolarization of a normal cell stimu-
lated at a frequency of 1 Hz.RESULTS
Modeling the Kv1.5 ion channel
Our strategy for implementing the continuous-time Markov
model was in many respects similar to several modeling
efforts of potassium channels found in the literature
(13,15,16,23,25).
Kv1.5 lacks the so-called fast N-type inactivation but is
affected by the slower C-type inactivation. From Fig. 3 in
Ramirez et al. (12), it is apparent that the inactivation prop-
erty becomes increasingly important for positive values of
the membrane potential. However, for the range of voltages
where the model will operate, inactivation is not very signif-
icant. At a membrane potential of 20 mV, the steady-state
value of the inactivation variable, uN, is ~0.95, which
means a reduction in IKurd by only 5% at steady state. For
membrane potentials at or below zero, steady-state inactiva-
tions are clearly negligible. Also considering that inactiva-
tion is a rather slow process, the effective reduction in IKurd
is even less for the typically short periods of more strongly
depolarized membrane potentials during an action potential.
As a consequence, the inactivation property was, for
simplicity, omitted from our model. This approximation
was validated by simulating theAP bothwith the inactivation
property in place and, as a comparison, with the inactivation
turned off. For the normal cell, the difference in membrane
potential did not exceed 1.5 mV during the course of the
AP and the maximum difference in IKurd was 0.1 pA/pF at
a stimulation frequency of 4 Hz. In the AF setting, which
was most frequently used in this study, differences were
even less. Less difference were also observed when all simu-
lations were repeated using a stimulation frequency of 1 Hz.
Under the assumption that transition rates between the
open and closed conformations of a subunit are independent
of the state of the other subunits and that all four subunits
operate in an identical manner, the Kv1.5 channel can be
represented by the five-state model in Fig. 1 A. It has four
closed, nonconducting states, C1-C1, and an open, conduct-
ing state, O. Here, a and b are the forward and reverse rate
constants of the transition to the open conformation, respec-
tively. A mathematical description of the scheme in Fig. 1 A
is given by a system of ordinary differential equations
dC1
dt
¼ 4aC1 þ bC2; (1a)
dC2
dt
¼ 4aC1  bC2  3aC2 þ 2bC3; (1b)
dC3
dt
¼ 3aC2  2bC3  2aC3 þ 3bC4; (1c)Biophysical Journal 99(9) 2726–2736
FIGURE 1 Five-state Kv1.5 model (A). Transitions between the states
are determined by the rates a and b. Six-state Kv1.5 model with an
open-channel block (B). Transitions between the open and the blocked state
are determined by the rates g and d and by the drug concentration. Ten-state
Kv1.5 model with several blocked states (C). Transitions between the
blocked states are determined by the rates z and 3.
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dt
¼ 2aC3  3bC4  aC4 þ 4bO; (1d)
dO
dt
¼ aC4  4bO; (1e)
where
a ¼ a0exp

ZaFV
RT

; (2a)
b ¼ b0exp
ZbFV
RT

; (2b)
and C1–C4 and O represents the fraction of channels in the
different states. The parameters a0 and b0 are the forward
and reverse rate constants of the transition to the open
conformation at zero membrane potential while Za and Zb
are the equivalent charge movements up to the transition
state, defining the degree of voltage dependence of a and
b. Together, the expressions in Eqs. 1 and 2 determine the
time evolution of the fraction of open Kv1.5 ion channels.
The conductance of the Kv1.5 channel was described by
the voltage-dependent relation for the total conductance of
Kv1.5 channel
gKurd ¼ 0:00855 þ 0:0779
1 þ expV þ 1116  (3)
used in Ramirez et al. (12). This expression correctly relates
experimental data of IKurd to the fraction of open channels
(26). Multiplying the fraction of open channels with the
conductance gKurd and with the deviation of the membrane
potential from the Nernst potential of Kþ ions, gave the
expression for IKurd,Biophysical Journal 99(9) 2726–2736IKurd ¼ gKurdOðV;a0;b0; Za; ZbÞðV  EKÞ; (4)to be compared with the Hodgkin-Huxley expression
IKurd ¼ gKurdu3auiðV  EKÞ (5)
used in Ramirez et al. (12).Determining parameters
To maintain the properties of the RNC model in absence of
a blocking agent, values of the parameters in the expressions
in Eq. 2 were chosen accordingly. In practice, this was done
by generating artificial data of themembrane potential of a re-
modeled cell during an 2 Hz AP using the RNC model with
the original equations for IKurd. The IKurd part of the model
was then replaced by the expressions in Eqs. 1 and 2, and
the parameters were optimized to fit the artificially generated
data. Optimizing the parameters during a complete AP, as
opposed to using an in silico voltage-clamp protocol for IKurd
alone, is appealing because the data set is naturally weighted
over the desired operating range of themodel. In this way, the
parameter values were found to be
a0 ¼ 0:6161 s1; b0 ¼ 0:1001 s1; Za ¼ 0:9470; and
Zb ¼ 0:8129:
The quality of the obtained parameter set is demonstrated in
Fig. S1 in the Supporting Material. There, the membrane
potential and IKurd of the Markov model is compared to
the original RNC model, using both the remodeled and
normal cell.
Including blocked state
A simple open-channel block of Kv1.5 was introduced by
adding a new state connected to the open state in Fig. 1 A.
The new state represents a nonconducting conformation
where the drug only interacts with the open state of the ion-
channel protein. This is the so-called foot-in-the-door mech-
anism, which has been described for several Kv1.5 blockers
including AVE0118 (27) and the diphenyl phosphine oxides
DPO-1 and DPO-2 (2,28). Returning to the open or closed
states requires that the bound drug dissociates from its
binding site. The extended model is shown in Fig. 1 B. In
the mathematical description, Eq. 1 e was modified and
a differential equation for the blocked state was added,
dO
dt
¼ aC4  4bO g½DrugO þ dB; (6a)
dB
dt
¼ g½DrugO dB; (6b)
where [Drug] denotes the concentration of the drug. The
rates g and d are of the same form as a and b in the expres-
sions in Eq. 2,
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
ZgFV
RT

; (7a)
d ¼ d0exp
ZdFV
RT

: (7b)
The potential voltage dependence of these rates (for nonzero
Zg and/or Zd) then reflects the fact that the drug binding site
may be located somewhere within the membrane electrical
field. If the drug has a net charge, it will sense part of the
electrical field and the binding and dissociation rates will
be altered. The extended model of Kv1.5 current is then
given by
IKurd ¼ gKurdOðV;a0; b0;g0; d0; Za; Zb; Zg; Zd; ½DrugÞ
 ðV  EKÞ; ð8Þ
reflecting the introduced dependence of the drug.Sensitivity analysis
Themodel was first used to illustrate how the AP of a remod-
eled PM cell changes in response to different concentrations
of a typical, uncharged drug with g ¼ 10 mM–1 s–1 and
d ¼ 2 s–1, at a stimulation frequency of 1 Hz. The simulated
membrane potential and IKurd current are shown in Fig. 2. In
the absence of IKurd block, the AP of the remodeled cell has
the characteristic triangular shape lacking a clearly defined
plateau. At low drug concentrations, a plateau emerges and0 50 100 150 200 250
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FIGURE 2 Action potential waveforms (A) and corresponding IKurd (B)
generated by the remodeled PM-cell model stimulated at a frequency of
1 Hz. Bold traces corresponds to no drug, solid traces to drug concentrations
of 1, 2, 3, 5, 8, and 13 mM, respectively, and dashed traces to 21 mM. The
drug-blocking action was defined by the parameter values g¼ 10 mM–1 s–1,
d¼ 2 s–1, and Zg¼ Zd¼ 0. The APD90 is marked by a dashed line in the plot
of the membrane potential. (Insets) Magnification of the traces during the
spike.the triangular shape is gradually lost. As the drug concentra-
tion increases further, the plateau phase becomes wider and
more elevated before the AP finally culminates in a spike
and dome morphology for the highest concentrations. In
this way, the addition of the drug delays the repolarization
and therefore increases the duration time of the AP. These
changes in the AP morphology are accompanied by an
attenuation of IKurd during the peak and the first part of
the plateau phase. The AP peak, shown in the inset of
Fig. 2 A, is not affected by the drug. However, it can be
noted that the peak is lower in our simulation of the AF-re-
modeled AP, reaching only 17 mV, compared to the normal
cell simulated in Ramirez et al. (12). The above effects on
the AP qualitatively resembles the effect of changing the
maximum IKurd conductance on the normal canine AP
(12). A prolonged duration of the AP, and an emerging
plateau, have also been reported from simulations of the
AF remodeled human atrial myocyte but no dome-shaped
plateau phase was observed even though conductance of
IKur was reduced to 20% (3) and 10% (9) of their nominal
values, respectively.
A drug-induced increase of the APD and, as a conse-
quence, in the AERP, has been considered as an effective
antiarrhythmic mechanism. To quantify the effects of
Kv1.5 blocking drugs on the AP we therefore used the
APD90-measure, as defined in the Methods. For all simula-
tion results presented in this section, the similarly defined
measure APD70 was also calculated. As it gave qualitatively
very similar results, these results are not shown. However,
this suggests that the choice of APD measure does not
have a critical influence on the conclusions drawn as long
as it is chosen somewhere in mid- or end-repolarization
phase. This can also be seen in Fig. 2 where the traces run
in parallel during the later part of repolarization. Because
the proposed antiarrhythmic mechanism is an increase in
the refractory period, the different concentrations of the
drug in Fig. 2 was used to investigate how the refractory
period varies with APD90. Both for the remodeled and
normal cell, this relationship was very well described by
a linear function (not shown). This suggests that APD90
can be used as a relevant measure of the refractory period.
Having tested the model for one specific parameter setup,
it was used, subsequently, to examine systematically how
the APD90 of a remodeled PM cell changes with respect
to the drug concentration, the free parameters of the expres-
sions in Eq. 7, and AP stimulation frequency. The results
were also compared to a simple model featuring a time-
and voltage-independent block obtained by just reducing
the conductance by a constant factor.
First, the effect of an uncharged drug was investigated for
two stimulation frequencies. Combining 21 values of the
effective on-rate, the concentration of the drug times the
binding rate, between 0 and 200 s–1,
½Drugg ¼ 10n; n ¼ 0; 1; ::; 20Biophysical Journal 99(9) 2726–2736
2730 Almquist et al.with 17 values of the dissociation rate between 0.25 and
64 s–1,
d ¼ 2n; n ¼ 2;1:5; ::; 6produced 375 different test situations. Results are shown as
combined surface and contour plots in Fig. 3. At a stimula-
tion frequency of 1 Hz, APD90 increased for both decreasing
values of the off-rate and for increasing values of the effec-
tive on-rate (see Fig. 3 A). At 4 Hz, the trend is comparable
to 1 Hz, but saturation at high effective on-rates is not as
evident and values of APD90 are substantially lower overall
(see Fig. 3 B). Avery low frequency, 0.1 Hz, was also tested,
and was found to be very similar to 1 Hz (results not shown).
The difference in APD90 between 1 Hz and 4 Hz, in absolute
numbers, is shown in Fig. 3 C. It shows that APD90 is 17 ms
longer at 1 Hz compared to 4 Hz in absence of drug (points
along the off-rate axis where the effective on-rate is zero).
For almost all other points in the plane, the difference is
larger, with a maximum difference of 41 ms.
Evidently, the presence of Kv1.5 targeting drugs in a re-
modeled PM cell tend to extend the duration of the AP
more at lower frequencies than at higher. This reverse use-
dependence also holds in terms of the relative increase in
APD90 (not shown). The frequency dependence was investi-
gated further by looking at APD90 and seeing how the frac-
tion of open and blocked Kv1.5 developed over time in both
the remodeled and the normal cell. Four different frequen-
cies, 0.5, 1, 2, and 4 Hz, was used with and without 8 mM
of the drug used in Fig. 2. The highest frequency, 4 Hz,
could not be tested for the normal cell in presence of the
drug because no stable limit cycle with a period of 250 ms
was present. In Fig. 4 A the frequency dependence of0100
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Biophysical Journal 99(9) 2726–2736APD90 is shown for the remodeled cell (left), and for the
normal setting (right). Interestingly, in the normal setting,
the reverse use-dependence seen for the remodeled cell is
not present. Instead, the increase in APD90 becomes larger
at higher frequencies. Fig. 4 B shows the fraction of
Kv1.5 in the open state during the first 100 ms of the AP
in absence of the drug. The morphological changes in the
AP due to rate adaption have the effect that lower fractions
of Kv1.5 are in the conducting, drug-susceptible state at
higher frequencies compared to lower. This observation
holds both for the remodeled and normal cell. The same
plot, but in the presence of the drug, is shown in Fig. 4 C.
Because of the block, smaller fractions of conducting
Kv1.5 are now seen. Finally, the fraction of blocked chan-
nels at different frequencies is shown in Fig. 4 D for the first
100 ms of the remodeled (left) and normal (right) AP. At the
lowest frequency, there were virtually no channels blocked
at the point of stimulation. At higher frequencies, significant
fractions of channels were still blocked at the onset of
stimulation.
The parametersZg andZd in Eq. 7 are the equivalent charge
movements up to the transition state of a drug in the electrical
field. By setting Zg and Zd to values other than zero, we exam-
ined the effects of various types of charged drugs on theAPD.
Assuming a drug with a net charge of þ1, its binding site
located at a point 20% into the electrical field, and a symmet-
rical barrier, we set Zg ¼ Zd ¼ 0. These values are similar to
experimentally determined values for two blockers of the
human Kv1.5 (13,16). However, introducing a voltage-
dependence of the interaction between the drug and its
binding site had limited effect on APD90. At 4 Hz, there
was virtually no change in APD90, except for very small0
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FIGURE 3 APD90 as function of effective on-
rate and off-rate of an uncharged drug at a stimula-
tion frequency of 1 Hz (A). APD90 as function of
effective on-rate and off-rate of an uncharged
drug at a stimulation frequency of 4 Hz (B). Abso-
lute difference between APD90 at stimulation
frequencies of 1 and 4 Hz as function of effective
on-rate and off-rate of an uncharged drug (C).
Absolute difference between APD90 calculated
from the time- and voltage-independent model
and from the six-state model, as function of effec-
tive on-rate and off-rate of an uncharged drug at
a stimulation frequency of 4 Hz (D).
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FIGURE 4 AP frequency dependence of 8 mM test drug defined by g ¼
10 mM–1 s–1, d ¼ 2 s–1, and Zg ¼ Zd ¼ 0. Left column uses the AF setting,
right column uses the normal cell setting. Row A shows APD90 as function
of frequency in absence of the test drug (dashed) and with the test drug
(solid). Row B shows the fraction open Kv1.5, O, during the first 100 ms
of the AP in absence of the test drug while rows C and D show the fraction
of open, O, and blocked, B, Kv1.5, respectively, in the presence of the test
drug during the first 100 ms of the AP. Bold traces correspond to a stimula-
tion frequency of 0.5 Hz, solid traces to 1 and 2 Hz, respectively, and dashed
traces to 4 Hz.
Modeling the Effect of Kv1.5 Block 2731off-rates, where the duration was decreased by ~3–4 ms. The
effectwas evenmoremarginal at 1Hz, producingonly a small
decrease in duration of 4ms for combinations of low effective
on-rate and low off-rate. These results suggest that Zg and Zd
may only have a significant impact if the receptor site is
located deep within the electrical field and/or the drug has
several charged groups at physiological pH.
In several studies (3,11,29,30), the effect of an ion
channel blocking drug has been modeled as a time- and
voltage-independent decrease in channel conductance. If
the degree of decrease in conductance in such a model is
assumed to be the result of a simple state-independent bimo-
lecular reaction in equilibrium (between the drug and itsbinding site), a comparison of this approach to our dynamic
modeling is possible. The constant degree of block in the
simpler model, Bconst, would then be a function of the effec-
tive on-rate kon (the concentration of the drug times the
binding rate) and the off-rate koff (dissociation rate),
Bconst ¼ kon
koff þ kon: (9)
To see how the two models differ, the difference in their
APD90 at a stimulation frequency of 4 Hz was calculated
from simulations. The result is shown in Fig. 3 D. For large
effective on-rates and small off-rates, as well as for the
opposite situation with small effective on-rates and large
off-rates, the two models gave similar results. In the other
parts of the on-off plane the difference was bigger, peaking
at 32 ms. We also looked at the difference between the
models at a stimulation frequency of 1 Hz. There was a simi-
larly located peak of the same height, but the differences in
other parts were roughly halved (not shown).
Extending the model
It is important to emphasize that the drug dissociation rate in
our open-channel block model only accounts for voltage
dependence arising from the charge of the drug. For the
human Kv1.5, voltage-dependent dissociation rates not
related to the charge of the drug has been reported (2,15).
The dissociation rates in Lagrutta et al. (2) were determined
at two different membrane potentials and denoted kon for the
open state and koff for the closed state. For one particular
compound, the DPO-1, these rates differed by a factor of
60. Apparently, at least for the hKv1.5 channel, the state
of the blocked channel can change with the membrane
potential producing a strong voltage dependence of the
dissociation rate in addition to any voltage dependence
due to the charge of the drug.
To describe this, additional blocked states could be added
in sequence to the blocked state of Fig. 1 B. This would
introduce a state-dependent recovery from block, similar
to the already existing state-dependent formation of block.
The model outlined in Fig. 1 C is one out of many possible
extensions to our model that could account for the state-
dependent type of voltage dependence discussed above. A
similar model structure has been used for the hERG channel
(31). Four new blocked states were added, creating sym-
metry to the four closed states in the upper part. The reason
for introducing precisely four new blocked states was conse-
quently to reflect an assumption that the four subunits may
fully or partially close independently and identically also
when a drug is bound. Because these conformational
changes would be expected to be different than in the
absence of a drug, two new rates of the same type as earlier,
z and e, was introduced. Compared to the six-state model,
the 10-state model can be seen as a more elaborate imple-
mentation of the foot-in-the-door mechanism.Biophysical Journal 99(9) 2726–2736
2732 Almquist et al.For the rates z and e to be determined, four parameter
values are required. To reduce complexity of the extended
model, it was assumed that the transition rates between
the closed states were faster than drug binding and dissoci-
ation. Under this assumption, the blocked branch of the
system can be reduced to a single lumped state. Let the
blocked lumped state be defined as
LB ¼ B1 þ B2 þ B3 þ B4 þ B: (10)
The occupancy of the original states are now determined
from the equilibrium relations in each of the lumped states.
In particular, the fraction of LB in the blocked state B, fB, is
fBðVÞ ¼ 1
1 þ 4Q þ 6Q2 þ 4Q3 þ Q4; (11)
where Q is the ratio of z and e. In the same way as O deter-
mines the fraction of unblocked channels accessible for drug
binding, fB determines the fraction of blocked channels that
are subject to drug dissociation. Using this variable, the
changes in O and in the lumped state LB with respect to
time can then be described by
dO
dt
¼ aC4  4bO þ dfBLB  g½Drug; (12a)
dLB
dt
¼ g½Drug  dfBLB; (12b)
to be compared with Eq. 6.Results from extended model
To explore further the impact of state-dependent recovery
from block, literature values for voltage-dependent
apparent association and dissociation rates (2) were imple-
mented in the 10-state model. In particular, data from two
compounds were chosen, DPO-1 and DPO-2, because of
their similarity in all parameters but the apparent dissocia-
tion rate, where they displayed a large difference. These
inhibitors have been characterized by measuring the
apparent association rate at þ40 mV, here denoted kon,
and the apparent dissociation rate at þ40 mV and at
80 mV, here denoted kopenoff and kclosedoff , respectively.
Although the kinetic parameters were determined for
hKv1.5 channels, they will be assumed to be the same for
the canine Kv1.5. In the 10-state model described above,
the drug association rate is g. Because basically all chan-
nels will open at þ40 mV, the measured association rate,
kon, translates directly to our parameter g. The apparent
dissociation rate for the collection of blocked states in the
10-state model is dfB, with fB being a voltage-dependent
function containing the variable Q. Written out, Q depends
on the membrane potential, V, on Q0, the ratio of z0 and e0,
and on ZQ, the sum of Z3 and Zz,Biophysical Journal 99(9) 2726–2736Q ¼ z
3
¼ z0
30
exp
ðZ3 þ ZzÞFV
RT

¼ Q0exp
ZQFV
RT

:(13)
At the measured membrane potentialsþ40 mVand80 mV,
the apparent dissociation rate is known. The parameters Q0,
ZQ, and d should therefore be set so that the two conditions
dfBð40Þ ¼ kopenoff and dfBð80Þ ¼ kclosedoff
are satisfied. With three parameters and only two relations,
there is no unique solution. However, the solution can be
parameterized in terms of, e.g., ZQ. From the parameterized
solution (not shown), it can be noted that the lower the value
of ZQ, the more linear the apparent dissociation rate will be
as function of V between the known values at þ40 mV and
80 mV. Conversely, the larger the value of ZQ, the more
nonlinear the apparent dissociation rate will be between
the known values.
The different combinations of Q0 and ZQ that reproduce
the kinetic parameters for the two compounds have different
interpretations. The parameter ZQ should be interpreted as
the total equivalent charge moved during transition of one
of the Kv1.5 subunits, when the drug is bound to the
receptor site. In the absence of a bound drug molecule, the
parameter optimization resulted in a total equivalent charge
movement, Za þ Zb, equal to 1.76. This sum constitutes an
upper bound for ZQ provided that binding of the drug, per se,
does not induce a conformational change or that the interac-
tion of the drug with the receptor site does not increase the
distance translocated by a subunit during opening/closing.
However, the binding of the drug may act as an obstacle,
decreasing the distance moved in the electrical field, result-
ing in a value of ZQ lower than Zaþ Zb. In any case, nothing
is said about the location of the barrier, the exact values of Ze
and Zz, because of the model reduction. While ZQ has the
interpretation of equivalent charge movement, Q0 should
be interpreted as the relative affinity for the closed state of
a subunit in the absence of an electrical force. One can
hypothesize that the presence of a bound drug alters this
relative affinity. Taken together, in the interpretation of the
10-state model a blocking drug leads to one or two things
besides stopping the potassium current through the channel.
The subunits may be hindered by the drug, making them
move a shorter distance in the electrical field, and the bound
drug may alter the subunits relative affinity for the open and
closed states. Both events will affect the apparent dissocia-
tion rate through their impact on fB.
Four versions of each compound were considered. For the
values 1.75, 1.3, 0.85, and 0.4 of ZQ, we calculated Q0 and d.
We did not consider values of ZQ lower than 0.4 because fB
at this point is already quite linear with respect to V, and
little further change is anticipated. All parameter values,
including the experimentally determined ones in Lagrutta
et al. (2), are shown in Table S1 in the Supporting Material.
Modeling the Effect of Kv1.5 Block 2733Having derived parameter sets for the four versions of each
drug, their effect on the APD90 of a remodeled PM-cell was
tested using a broad range of concentrations. The results from
simulations are shown in Fig. 5. Upper and lower rows are
results for a stimulation frequency of 1 Hz and 4 Hz, respec-
tively. Column A shows APD90 for the four versions of
compound 1, column B shows APD90 for the four versions
of compound 2, and column C shows the differences in
ADP90 between columns A and B. The colors black, blue,
green, and red corresponds to the different versions with ZQ
set to the values 1.75, 1.3, 0.85, and 0.4. The concentrations
tested are Kd2
n, where Kd is the dissociation constant, and
where n ¼ 3, 2,., 7 is shown on the x axis. At 1 Hz,
APD90 was 134 ms in the absence of a drug, increasing to
values close to 200 ms at high concentrations for all param-
eter versions. For compound 1 (column A) the particular
version was of considerable importance at intermediate
concentrations. The fourth version (red curve), with ZQ ¼
0.4, gave the strongest prolongation of the AP, and the first
version (black curve) gave the weakest. This is reasonable,
considering that the voltage dependence of fB give rise
to smaller apparent dissociation rates in the range
between þ40 mV and 80 mV for ZQ ¼ 0.4 than for ZQ ¼
1.75. For compound 2 (column B), however, the dose-
response curve was virtually independent of the parameter
setup. The reason for this is that even though the behavior
of fB also differs for the different ZQ values for compound
2, it has a ratio of kopenoff to k
closed
off equal to 2.27, while this
number is 61.7 for compound 1. This means that the relative
size of fB at different ZQ is less for compound 2 than for−2 0 2 4 6
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0compound 1, and hence that the variation of the apparent
dissociation rate is less in its different versions. At 4 Hz,
APD90 was 118 ms in absence of a drug, increasing to values
close to 170 ms at high concentrations for all parameter
setups. Also at this frequency, the versions of compound 2
showed practically no differences, in contrast to compound
1 where the parameter setup was again critical for the result-
ing APD90. In column C, the differences in APD90 of all
versions of the two compounds are displayed. At 1 Hz, the
maximum difference ranged from 31 ms to 19 ms, and at
4 Hz from 26 ms to 10 ms. Based on these simulations it
can be concluded, at least when looking at concentrations
on a Kd scale, that DPO-1 is a more efficacious blocker
than DPO-2, irrespective of the version implemented. This
conclusion is consistent with the fact that DPO-1 is a more
potent blocker of human Kv1.5 than DPO-2 (2). DPO-1 has
also been shown to increase dog atrial refractoriness and to
increase human atrial AP duration (2,8). It should also be
noted from the simulations that both compounds display
a reverse use-dependence, showing a larger increase in
APD90 at 1 Hz than at 4 Hz.DISCUSSION
To enable more-realistic studies on the effects of Kv1.5
blockers on the canine atrial AP in silico, two continuous-
time Markov models of the guarded receptor type were set
up for the Kv1.5 channel. Ion-channel model parameters
were determined by using artificially generated data from
the RNC model and available experimental data on the2 0 2 4 6
[Drug]
C
2 0 2 4 6
[Drug]
FIGURE 5 APD90 values and difference
between APD90 values generated by the remodeled
PM-cell model using the 10-state blocking model
and four versions of compound 1 and compound
2, respectively. Versions 1–4 are encoded by black,
blue, green, and red. Upper and lower row are for
frequencies 1 Hz and 4 Hz, respectively. Columns
A and B correspond to compound 1 and compound
2, respectively. Column C shows the difference
between A and B. Drug concentration is given by
the expression Kd2
n , where Kd is the dissociation
constant, and where n ¼ 3, 2,., 7.
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2734 Almquist et al.kinetics of drug-ion channel interaction. The Kv1.5 Markov
models were subsequently inserted to the simple AF-remod-
eled version of the RNC model.
The main findings from this study are:
1. Time- and state-dependent Markov models of open-
channel Kv1.5 block gave significantly different results
compared to a time- and state-independent model with
a downscaled conductance.
2. The outcome of Kv1.5 block on the macroscopic system
variable APD90 was dependent on the precise mechanism
of block.
3. Open-channel block produced a reverse use-dependent
prolongation of the APD90.
Our data clearly suggest that the choice of ion channel
model has a large impact on the simulation results. When
the dynamic six-state model was compared to a time- and
state-independent model, differences in the simulated
APD90 as large as 32 ms were observed. This suggests
that the simple down-scaling of IKurd conductance
commonly used in many studies may be too unsophisticated
for quantitative modeling of drug effects.
To be able to simulate drugs showing an apparent voltage
dependence in their dissociation rates, a 10-state Markov
model was formulated. To our knowledge, this is the first
Markov model of Kv1.5 able to capture this phenomena.
It was shown how the experimentally measured kinetic
parameters of two clinically relevant drugs (2) could be im-
plemented and the model was subsequently used to simulate
the effect of these compounds. The simulations showed that
the slower recovery of block at polarized potential of DPO-1
made it a more efficacious drug than DPO-2.
There are two frameworks commonly used for modeling
state-dependent block—the modulated receptor theory and
the guarded receptor theory. Sections reviewing these
concepts and the means by which they have been applied
in ion-channel modeling can be found in Brennan et al.
(32). Briefly, in the modulated receptor theory, drugs
interact with their receptor for all conformational states of
a channel, each state differing in its kinetics of drug binding
and dissociation. In the guarded receptor theory, drug inter-
action is limited to certain channel states only. The 10-state
guarded receptor model of Kv1.5 developed in this study
can be considered a special case of the more-general modu-
lated receptor model. Hypothesizing nonzero affinities for
all of the closed states in Fig. 1 C would transform the
model into a modulated receptor. While adding vertical
transitions between the closed and blocked states might
allow for more complex and sophisticated behaviors, it
would also make system identification from experimental
data more demanding. As was seen for the two compounds,
all parameters in our model could not even be uniquely
determined. Because of the identifiability issue, and the
fact that the 10-state model developed contained enough
complexity to describe state-dependent recovery fromBiophysical Journal 99(9) 2726–2736block, a general modulated receptor model was not consid-
ered in this study.
Tsujimae et al. (9) took another approach to incorporate
the effects of voltage- and time-dependent block, including
the voltage-dependent recovery from block. They extended
a Hodgkin-Huxley formulation of human IKur by intro-
ducing a new multiplicative variable, describing the fraction
of unblocked channels, in the expression for this current.
Their modified formulation is given by
IKur ¼ yKurgKuru3auiðV  EKÞ; (14)
where yKur is the fraction of IKur that is not blocked by a
drug. The remaining variables have the same meaning as
those of Eq. 5. Because the variables of Hodgkin-Huxley
formulations are independent, open-state block was
mimicked by designing the voltage-dependent steady-state
profile for the fraction of unblocked channels to resemble,
qualitatively, the opposite of the activation profile. Time
constant profiles describing the kinetics of formation of
and recovery from block were set up based on the same
compounds investigated by us in this study. The authors
connected known values of the time constant of block at
two membrane potentials with a Boltzmann function with
a half-value and slope of 40 mV and 5 mV, respectively.
However, compared with our implementation of the two
DPOs, it was not discussed in detail how to determine the
voltage-dependent profiles for the relaxation time-constant
and for the steady-state fraction of unblocked channels for
some particular drug. Neither did their implementation
address the effects from charged drugs. Furthermore, our
model allows for any value of the drug concentration,
whereas the Tsujimae model only considers one particular
steady-state profile for the fraction of unblocked channels.
The outcome of the simulations with the 10-state model
leads to important conclusions regarding the experimental
protocols used to probe potential IKurd blockers. Because
the precise choice of Q0 and ZQ had a major impact on
the AP-prolonging effects of one of the compounds, addi-
tional measurements of the apparent dissociation rate at
other membrane potentials may be crucial. Such additional
measurements of the apparent dissociation rate would allow
Q0 and ZQ to be determined. To increase the chances of good
parameter identifiability besides just increasing the number
of measurements, the preceding analysis of the 10-state
model can be used for optimal experiment design with
respect to the voltages at which measurements are to be per-
formed, thereby increasing the predictive power of the
model.
It was also found that open-channel block produced larger
increases of the canine APD90 at lower frequencies than at
higher. This was observed for the six-state model as well
as for two specific blockers encoded in the 10-state model,
using the remodeled setting. On the other hand, when the
six-state model was used with the normal cell setting,
Modeling the Effect of Kv1.5 Block 2735a positive frequency dependence was observed. Because an
open-state block can, in itself, never give rise to reverse use-
dependence, it must be understood that it is an emergent
property of the ensemble of all currents and the role played
by Kv1.5 in this context. The environment of other ionic
currents can be thought to interact with Kv1.5 and Kv1.5
block in two ways.
First, the voltage-dependent activation of Kv1.5 means
that the fraction of Kv1.5 susceptible to block is dependent
on how V develops during the AP. This, in turn, depends on
the density and activity of all other currents. The rate adap-
tion to higher stimulation frequencies, described in Ramirez
et al. (12), leads to a decreased APD and a lower fraction of
open Kv1.5 channels susceptible to block during the AP.
This was seen both in the AF setting and for the normal
cell (see Fig. 4 B) However, a lower fraction of open chan-
nels did not lead to a lower fraction of blocked channels
when the drug was added. This was seen in Fig. 4 D where
the fraction of blocked channels is shown at different
frequencies. Because the fraction of blocked channels
during the initial phase of the AP in fact increases with
frequency, it appears that the use-dependence of open-state
block itself overcomes the decreasing fraction of susceptible
channels at higher frequencies shown in Fig. 4 B.
Second, the impact of actually blocking Kv1.5 again
depends on all other currents and the relative importance
of IKurd compared to them. In Fig. 4 C, it was shown that
in addition to the increase of the blocked fraction with
higher frequencies in Fig. 4 D, the fraction of open channels
is decreasing. Despite the decrease in the fraction of con-
ducting Kv1.5 at higher frequencies observed for both the
remodeled and normal cell, the increase in APD has a posi-
tive frequency dependence only in the normal cell. This
illustrates the fact that there are several factors in addition
to the drug-ion channel interaction itself that determine
the outcome of ion channel block on a particular systems
property, i.e., APD90. It is most likely that such properties
are different depending on species, tissue-type, the degree
of electrical remodeling, etc. The finding that that DPO-1
produced a positive frequency-dependent increase of APD
in human atrial cells (2) does thus not necessarily imply a
contradiction to our simulation data. DPO-1 has been shown
to increase atrial AERP and thus most likely APD90 in a
canine disease model, but no information is available
regarding frequency dependency or effects in normal tissue
(8). Interestingly, Wu et al. (33) showed that a Kv1.5 block
produced a reverse use-dependent increase in pig atrial
AERP in vivo.
The changes in conductances used in the AF setting were
chosen as to mimic, in a simplistic way, the major ionic
alterations observed during tachycardia-dependent remodel-
ing in the dog according to references given. These ionic
changes were experimentally observed and model AP
morphology was then fitted to experimental data from cells
where these ionic changes had been observed. It is clearfrom our data and Ramirez et al. (12) that a block of IKurd
in the native canine myocyte model, apart from increasing
the duration of the plateau phase of the AP, most likely
also prolongs late repolarization phases of the AP, suggest-
ing an increased effective refractory period and, hence, less
likelihood of AF initiating. This prolongation has also been
observed experimentally in isolated canine myocytes (34).
Although the simplistic remodeled atrial cell model used
in this study does not fully capture all changes that occur
during the remodeling process and the predictive value,
thus, is uncertain, our data clearly suggest that more-
complex ion-channel models are a prerequisite for quantita-
tive modeling of drug effects.SUPPORTING MATERIAL
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